分享产品介绍 评论(0)
【ASSAY PRINCIPLE】
The kit is based on homogeneous time-resolved fluorescence technology (TR-FRET) technology，which is used to assess the molecular-mediated interaction between the KRAS[WT] and CypA. This method provides a high-throughput approach to detect the small molecules capable of mediating the interaction between the KRAS[WT] and CypA simply and rapidly.
As shown in the figure below, the interaction between KRAS[WT] and CypA was detected by an Eu-labeled anti-Tag1 antibody (TR-FRET donor) and an Ac-labeled anti-Tag2 antibody (TR-FRET receptor). Since the molecular adhesive Daraxonrasib mediates the interaction between KRAS[WT] and CypA, the donor antibody is in close proximity to the receptor antibody. Excitation of the donor antibody triggers fluorescence resonance energy transfer (FRET) to the receptor antibody, resulting in specific emission of a signal at a wavelength of 665 nm from the receptor antibody. This specific signal is proportional to the degree of interaction between Daraxonrasib, KRAS[WT] and CypA. This homogeneous assay is simple to perform and requires no washing steps.
来源
Human储存条件
-80℃
【Composition and Storage Conditions】
Composition
concentration
100T
500T
2500T
10000T
Storage
Tag1-KRAS[WT] protein
50×
8μL
40μL
200μL
800μL
-80℃
Tag2-CypA protein
50×
8μL
40μL
200μL
800μL
-80℃
Daraxonrasib
400 μM
5μL
10μL
50μL
200μL
-80℃
Anti-Tag1 Eu antibody
100×
5μL
25μL
75μL
500μL
-80℃
Anti-Tag2 Ac antibody
200×
5μL
13μL
38μL
250μL
-80℃
Detection buffer
10×
400μL
2mL
10mL
40mL
-80℃
Note: Aliquot into appropriate volumes, store at the recommended temperature and avoid repeated freeze-thaw cycle.
【Process and Operations】
1、Reagent Preparation
1.1 Compositions equilibration
Before use, dissolve all reagents at room temperature (allow at least 30 minutes for temperature equilibration). For the 384-well plate assay, use 20 μL of reaction mixture (the reagent quantities are listed in the table below). Calculate the required volume prior to preparation accordingly. The following preparation steps are provided for reference only, using a 500-well plate as an example.
Table 1. Reagent Preparation
Composition
Configuration
μL/well
Detection buffer
Add 2 mL of 10× Detection buffer to 18 mL of deionized water, dilute to 1× Detection , and mix thoroughly for later use.
-
Tag1-KRAS[WT] protein
Take 40 μL of the 50× Tag1-KRAS[WT] protein stock solution, add 1.96 mL of 1× Detection buffer to dilute it to 1× concentration, and mix thoroughly for later use.
4
Tag2-CypA protein
Take 40 μL of 50× Tag2-CypA protein, add it to 1.96 mL of 1× Detection buffer to dilute to 1× concentration, and mix thoroughly for later use.
4
Antibody Mix
Take 25 μL of the 100× Anti-Tag1 Eu antibody stock solution, add 2475 μL of 1× Detection buffer to dilute to 2.5 mL, and mix thoroughly; take 13 μL of the 200× Anti-Tag2 Ac antibody stock solution, add 2587 μL of 1× Detection buffer to dilute to 2.6 mL, and mix thoroughly; combine the two solutions in a 1:1 ratio to obtain the Antibody Mix.
10
1.2 Gradient dilution of the sample
Daraxonrasib as an example, the dilution solution is 1× Detection buffer. To minimize interference from matrix effects, it is recommended to use a solution with the same matrix composition as the sample being tested; additionally, the sample concentration should be adjusted according to its actual situation.
Table 2. Daraxonrasib gradient dilution（Adjust according to the actual situation）
Daraxonrasib final concentration（nM）
Daraxonrasib preparation concentration（nM）
Dilution
①
400.00
4000.00
1μL 400 μM Daraxonrasib +99μL 1× Detection buffer
②
200.00
2000.00
30μL ① +30μL 1× Detection buffer
③
100.00
1000.00
30μL ② +30μL 1× Detection buffer
④
50.00
500.00
30μL ③ +30μL 1× Detection buffer
⑤
25.00
250.00
30μL ④ +30μL 1× Detection buffer
⑥
12.50
125.00
30μL ⑤ +30μL 1× Detection buffer
⑦
6.25
62.50
30μL ⑥ +30μL 1× Detection buffer
⑧
3.13
31.25
30μL ⑦+30μL 1× Detection buffer
⑨
1.56
15.63
30μL ⑧+30μL 1× Detection buffer
⑩
0.78
7.81
30μL ⑨+30μL 1× Detection buffer
⑪
0.39
3.91
30μL ⑩+30μL 1× Detection buffer
Blank
0
0
40μL 1× Detection buffer
2、Sample and control
2.1 Sample：Add 4 μL of Tag1-KRAS[WT] protein working solution, 4 μL of Tag2-CypA protein working solution, 2 μL of the gradient-diluted sample , and 10 μL of the mixed Antibody Mix sequentially into the 384-well plate.
2.2 Daraxonrasib: 4 μL of Tag1-KRAS[WT] protein working solution, 4 μL of Tag2-CypA protein working solution, 2 μL of gradient-diluted Daraxonrasib, and 10 μL of the mixed Antibody Mix sequentially into the 384-well plate.
2.3 Blank：4 μL of Tag1-KRAS[WT] protein working solution, 4 μL of Tag2-CypA protein working solution, 2 μL of Detection buffer, and 10 μL of the mixed Antibody Mix sequentially into the 384-well plate.
2.4 Negative control： 10μL Detection buffer, and 10 μL of the mixed Antibody Mix sequentially into the 384-well plate.
After adding all samples, centrifuge, seal with a cover membrane, and incubate at room temperature for 1 hours.
Table 3. Sample and control spotting process
Daraxonrasib
Sample
Blank
Negative control (NC)
2μL
gradient-diluted Daraxonrasib
2μL
gradient-diluted sample
2μL
1× Detection buffer
10μL 1× Detection buffer
and 10μL Antibody Mix
4μL Tag1-KRAS[WT] protein
4μL Tag2-CypA protein
10μL Antibody Mix
Seal the plate wells with a sealing film and incubate at room temperature for 1hours.
3、Read Data
The detection was performed on a TR-FRET microplate reader. The excitation wavelength was 320/340 nm, and the emission wavelengths at 620 nm and 665 nm were detected.
【DATA REDUCTION 】
1) Ratio：
Ratio = (665/620) ×10000
2) Net signal：
Net signal = (Std-NC)/NC×100
Std：the ratio of sample and control
NC: the ratio of negative control
3) CV（%）：
CV（%）= Standard Deviation/Mean Ratio × 100%
【Data Example】
The following data cannot replace experimental results obtained in experiments; they are provided solely for illustrative purposes, and outcomes may vary depending on the plate reader used.
/3Note: Recommended microplate
(384-well plate, white, shallow wells).
评论(0)